Pemigatinib is included as a new drug in ProTarget

From September 2022, it will be possible to screen for and include patients for Pemazyre (pemigatinib) treatment in ProTarget. Eligible patients have a histologic tumor type outside the labeled indication, and must have at least one of the below genomic alterations identified in their tumor:

• PDGFRA mutations
• PDGFRB mutations
• PCM1-JAK2 fusions
• FGF amplification, mutations or fusions
• FGFR amplification, mutations or fusions

Read more about Pemazyre (pemigatinib) here:

https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre#overview-section

All potential candidates must be evaluated and confirmed at the Danish National Molecular Tumor Board before inclusion. Please, refer to the protocol for complete inclusion/exclusion criteria. Pemigatinib is supplied by Incyte.